Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
10'-apo-beta-carotenal + NAD+ + H2O
10'-apo-beta-carotenoic acid + NADH + 2 H+
i.e. (2E,4E,6E,8E,10E,12E,14E)-4,9,13-trimethyl-15-(2,6,6-trimethylcyclohex-1-en-1-yl)pentadeca-2,4,6,8,10,12,14-heptaenal
-
-
?
12'-apo-beta-carotenal + NAD+ + H2O
12'-apo-beta-carotenoic acid + NADH + 2 H+
i.e. (2E,4E,6E,8E,10E,12E)-2,7,11-trimethyl-13-(2,6,6-trimethylcyclohex-1-en-1-yl)trideca-2,4,6,8,10,12-hexaenal
-
-
?
14'-apo-beta-carotenal + NAD+ + H2O
14'-apo-beta-carotenoic acid + NADH + 2 H+
i.e. (2E,4E,6E,8E,10E)-5,9-dimethyl-11-(2,6,6trimethylcyclohex-1-en-1-yl)undeca-2,4,6,8,10-pentaenal
-
-
?
all-trans retinal + NAD+ + H2O
all-trans retinoate + NADH + 2 H+
-
-
-
?
all-trans-retinal + H2O + NAD+
all-trans-retinoate + NADH + 2 H+
all-trans-retinal + NAD+ + H2O
all-trans-retinoate + NADH + 2 H+
-
-
-
?
decanal + NAD+ + H2O
decanoate + NADH + 2 H+
-
-
-
?
dihydrolipoic acid + H2O + NAD+
? + NADH + 2 H+
-
-
-
?
glutathione + H2O + NAD+
GSSG + NADH + 2 H+
-
-
-
?
hexanal + H2O + NAD+
hexanoate + NADH + 2 H+
-
-
-
?
propionaldehyde + NAD+
propionate + NADH + H+
-
-
-
?
retinal + NAD+ + H2O
retinoate + NADH + 2 H+
-
-
-
?
10'-apo-beta-carotenal + NAD+ + H2O
10'-apo-beta-carotenoic acid + NADH + 2 H+
i.e. (2E,4E,6E,8E,10E,12E,14E)-4,9,13-trimethyl-15-(2,6,6-trimethylcyclohex-1-en-1-yl)pentadeca-2,4,6,8,10,12,14-heptaenal
-
-
?
12'-apo-beta-carotenal + NAD+ + H2O
12'-apo-beta-carotenoic acid + NADH + 2 H+
i.e. (2E,4E,6E,8E,10E,12E)-2,7,11-trimethyl-13-(2,6,6-trimethylcyclohex-1-en-1-yl)trideca-2,4,6,8,10,12-hexaenal
-
-
?
14'-apo-beta-carotenal + NAD+ + H2O
14'-apo-beta-carotenoic acid + NADH + 2 H+
i.e. (2E,4E,6E,8E,10E)-5,9-dimethyl-11-(2,6,6trimethylcyclohex-1-en-1-yl)undeca-2,4,6,8,10-pentaenal
-
-
?
2,4-decadienal + NAD+ + H2O
2,4-decadienoate + NADH + H+
-
-
-
-
?
3-deoxyglucosone + NAD+ + H2O
2-keto-3-deoxygluconate + NADH + H+
-
-
-
-
?
acetaldehyde + NAD+ + H2O
acetate + NADH + H+
-
-
-
-
?
aldophosphoamide + NAD+ + H2O
?
-
-
-
-
?
all-trans retinal + NAD+ + H2O
all-trans retinoate + NADH + 2 H+
-
-
-
?
all-trans-retinal + H2O + NAD+
all-trans-retinoate + NADH + 2 H+
all-trans-retinaldehyde + NAD(P)H
NAD(P)+ + H2O + all-trans-retinoate
-
-
-
-
?
all-trans-retinol + NAD(P)H
NAD(P)+ + H2O + all-trans-retinaldehyde
-
-
-
-
?
benzaldehyde + NAD+ + H2O
benzoate + NADH + H+
-
-
-
-
?
BODIPY-aminoacetaldehyde + NAD+ + H2O
?
-
-
-
-
?
citral + NAD+ + H2O
(2E)-3,7-dimethylocta-2,6-dienoic acid + NADH + H+
-
-
-
-
?
decanal + NAD+ + H2O
decanoate + NADH + H+
-
-
-
-
?
hexanal + H2O + NAD+
hexanoate + NADH + 2 H+
-
-
-
?
hexanal + NAD+ + H2O
hexanoate + NADH + H+
-
-
-
-
?
propionaldehyde + NAD+
propionate + NADH + H+
-
-
-
?
retinal + NAD+ + H2O
all-trans-retinoate + NADH + 2 H+
-
-
-
?
retinal + NAD+ + H2O
retinoate + NADH
retinal + NAD+ + H2O
retinoate + NADH + 2 H+
retinal + NAD+ + H2O
retinoate + NADH + H+
-
-
-
-
?
retinal + NAD+ + H2O
retinoic acid + NADH + H+
-
-
-
?
retinol + NAD+ + H2O
? + NADH + H+
-
-
-
-
?
additional information
?
-
all-trans-retinal + H2O + NAD+
all-trans-retinoate + NADH + 2 H+
-
-
-
?
all-trans-retinal + H2O + NAD+
all-trans-retinoate + NADH + 2 H+
-
-
-
?
all-trans-retinal + H2O + NAD+
all-trans-retinoate + NADH + 2 H+
-
-
-
?
all-trans-retinal + H2O + NAD+
all-trans-retinoate + NADH + 2 H+
-
-
-
?
all-trans-retinal + H2O + NAD+
all-trans-retinoate + NADH + 2 H+
-
-
-
?
all-trans-retinal + H2O + NAD+
all-trans-retinoate + NADH + 2 H+
-
-
-
?
all-trans-retinal + H2O + NAD+
all-trans-retinoate + NADH + 2 H+
-
-
-
?
retinal + NAD+ + H2O
retinoate + NADH
-
-
-
-
?
retinal + NAD+ + H2O
retinoate + NADH
-
preferred substrate
-
-
?
retinal + NAD+ + H2O
retinoate + NADH + 2 H+
-
-
-
-
?
retinal + NAD+ + H2O
retinoate + NADH + 2 H+
-
-
-
?
additional information
?
-
molecular basis of retinal recognition, comparison of enzyme from Rattus and human, overview. In contrast to long chain unsaturated substrates, the rate-limiting step of retinal oxidation by RALDHs is associated with acylation. Retinal recognition occurs in two steps: binding into the substrate access channel, and a slower structural reorganization with a rate constant of the same magnitude. The conformational transition of the RALDH-retinal complex significantly contributes to the rate-limiting step that controls the kinetics of retinal oxidation, as a prerequisite for the formation of a catalytically competent Michaelis complex. The conclusion is consistent with the general notion that structural flexibility within the active site of ALDH enzymes has been shown to be an integral component of catalysis. No activity with 2,4-decadienal, citral, and hexanal
-
-
?
additional information
?
-
-
molecular basis of retinal recognition, comparison of enzyme from Rattus and human, overview. In contrast to long chain unsaturated substrates, the rate-limiting step of retinal oxidation by RALDHs is associated with acylation. Retinal recognition occurs in two steps: binding into the substrate access channel, and a slower structural reorganization with a rate constant of the same magnitude. The conformational transition of the RALDH-retinal complex significantly contributes to the rate-limiting step that controls the kinetics of retinal oxidation, as a prerequisite for the formation of a catalytically competent Michaelis complex. The conclusion is consistent with the general notion that structural flexibility within the active site of ALDH enzymes has been shown to be an integral component of catalysis. No activity with 2,4-decadienal, citral, and hexanal
-
-
?
additional information
?
-
the dissociation of NADH from the enzyme is the rate-limiting step for ALDH1A1-mediated aldehyde oxidation. ALDH1A1 can also use glutathione (GSH) and dihydrolipoic acid (DHLA) as electron donors to reduce NAD+ to NADH, product identification by thin layer chromatography (TLC). Even though they share the same NAD+-binding sites and the same active sites, the enzymatic mechanism of the GSH/DHLA-dependent NAD+-reduction activity of ALDH1A1 is distinct from its aldehyde-dehydrogenase activity
-
-
-
additional information
?
-
-
also active with medium-chain saturated aliphatic aldehydes
-
-
?
additional information
?
-
-
no significant conversion of 17beta-, 3alpha- and 11beta-hydroxysteroids, and corresponding ketosteroids
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-(6-fluoro-3-(4-(methylsulfonyl)piperazine-1-carbonyl)-quinolin-4-yl)-4-phenylpiperidine-4-carbonitrile
i.e. NCT-505
-
2,3,5,6,9-pentamethyl-7H-furo[3,2-g][1]benzopyran-7-one
21.6% inhibition at 0.01 mM
-
2,3,5,6-tetramethyl-7H-furo[3,2-g][1]benzopyran-7-one
9.5% inhibition at 0.01 mM
-
2,3,5-trimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
63.7% inhibition at 0.01 mM
-
2,3,5-trimethyl-6-[3-oxo-3-(piperidin-1-yl)propyl]-7H-furo[3,2-g][1]benzopyran-7-one
91.3% inhibition at 0.01 mM
-
2,3-dimethyl-5-propyl-7H-furo[3,2-g][1]benzopyran-7-one
25.9% inhibition at 0.01 mM
-
2-(4-(4-ethylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
16.79% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-(4-(4-isopropylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
14.47% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-(4-(4-methoxybenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
29.37% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-(4-(4-methylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
8.5% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]-N-phenylacetamide
50.4% inhibition at 0.01 mM
-
2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetamide
71.5% inhibition at 0.01 mM
-
2H-furo[2,3-h][1]benzopyran-2-one
39.0% inhibition at 0.01 mM
-
3,4,10-trimethyl-2H,6H-benzo[1,2-b:5,4-b']dipyran-2,6-dione
32.6% inhibition at 0.01 mM
-
3,4,8,9-tetramethyl-7H-furo[2,3-f][1]benzopyran-7-one
38.5% inhibition at 0.01 mM
-
3,4-dimethyl-6,7,8,9-tetrahydro-2H-[1]benzofuro[3,2-g][1]benzopyran-2-one
35.7% inhibition at 0.01 mM
-
3,5-dimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
51.4% inhibition at 0.01 mM
-
3-(4-(4-(trifluoromethyl)benzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
3.86 % inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-bromobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
24.42% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-chlorobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
37.43% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-cyanobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
24.52% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-ethylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
68.27% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-fluorobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
31.19% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-isopropylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
77.15% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-methoxybenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
60.51% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-methylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
47.31% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-nitrobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
28.33% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
0.05% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(furan-2-carbonyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
9.44% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-benzoylpiperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
39.23% inhibition at 0.01 mM at pH 7.5, 25°C at pH 7.5, 25°C
-
3-(4-isonicotinoylpiperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
36.65% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-nicotinoylpiperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
30.95% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(benzo[d][1,3]dioxole-5-carbonyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
35.93% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-benzyl-4-methyl-2-oxo-2H-1-benzopyran-7-yl methanesulfonate
75.4% inhibition at 0.01 mM
-
3-tert-butyl-5,6-dimethyl-7H-furo[3,2-g][1]benzopyran-7-one
5.5% inhibition at 0.01 mM
-
3-[(3-oxobutan-2-yl)oxy]-6H-dibenzo[b,d]pyran-6-one
41.3% inhibition at 0.01 mM
-
3-[4-(furan-2-carbonyl)piperazin-1-yl]-N-(3-methylbut-2-en-1-yl)-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)propanamide
-
-
4-(1,3-dihydro-2H-isoindol-2-yl)benzaldehyde
-
-
4-(4-(4-ethylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
27.23% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-(4-(4-isopropylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
33.01% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-(4-(4-methoxybenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
13.10% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-(4-(4-methylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
32.19% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-dimethylamino-4-methyl-pent-2-ynthioic acid S-methyl ester
-
-
4-methyl-7-(2-oxo-2-phenylethoxy)-2H-1-benzopyran-2-one
71.0% inhibition at 0.01 mM
-
4-methyl-7-(2-oxopropoxy)-2H-1-benzopyran-2-one
47.8% inhibition at 0.01 mM
-
4-methyl-7-[(3-methylbut-2-en-1-yl)oxy]-2H-1-benzopyran-2-one
61.7% inhibition at 0.01 mM
-
4-methyl-7-[(prop-2-en-1-yl)oxy]-2H-1-benzopyran-2-one
64.5% inhibition at 0.01 mM
-
5-benzyl-2,3-dimethyl-7H-furo[3,2-g][1]benzopyran-7-one
43.0% inhibition at 0.01 mM
-
5-methyl-2-[(3-oxobutan-2-yl)oxy]-7H-furo[3,2-g][1]benzopyran-7-one
31.3% inhibition at 0.01 mM
-
6-benzyl-3,5-dimethyl-7H-furo[3,2-g][1]benzopyran-7-one
-
6-methyl-3,4-dihydro-2H,8H-benzo[1,2-b:5,4-b']dipyran-2,8-dione
34.8% inhibition at 0.01 mM
-
7-(2-oxopropoxy)-2H-1-benzopyran-2-one
7.6% inhibition at 0.01 mM
-
7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one
85.7% inhibition at 0.01 mM
-
7-methoxy-4-methyl-2H-1-benzopyran-2-one
19.8% inhibition at 0.01 mM
-
8,9-dimethyl-2,3-dihydrocyclopenta[c]furo[3,2-g][1]benzopyran-4(1H)-one
49.2% inhibition at 0.01 mM
-
8-[[4-(3-furoyl)-1-piperazinyl]methyl]-1,3-dimethyl-7-(3-methylbutyl)-3,7-dihydro-1H-purine-2,6-dione
i.e. CM026, 75.22% inhibition at 0.01 mM at pH 7.5, 25°C at pH 7.5, 25°C
-
9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one
43.7% inhibition at 0.01 mM
-
9,10-dimethyl-5H-6,8-dioxacyclopenta[b]phenanthren-5-one
17.6% inhibition at 0.01 mM
-
diethylaminobenzaldehyde
DEAB, an ALDH1A1 inhibitor which competitively binds to the aldehyde-binding pocket of ALDH1A1 and completely inhibits the aldehyde oxidation activity of the enzyme at 0.01 mM, but has no effect on the GSH/DHLA-dependent NAD+-reduction activity
dimethyl ampal thiolester
-
ethyl ([4-oxo-3-[3-(pyrrolidin-1-yl)propyl]-3,4-dihydro[1]benzothieno[3,2-d]pyrimidin-2-yl]sulfanyl)acetate
i.e. CM37
-
N,N'-(octane-1,8-diyl)bis(2,2-dichloroacetamide)
WIN 18,446
-
N,N-diethylaminobenzaldehyde
DEAB
-
N-(2-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-methoxybenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3,5-dimethylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-methoxybenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(4,7-dimethyl-2-oxo-2H-1-benzopyran-6-yl)-2-methylpropanamide
40.2% inhibition at 0.01 mM
-
N-(4-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(4-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(4-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclobutylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclohexylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclopentylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclopropylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-benzyl-3-(2,3,5-trimethyl-7-oxo-7H-furo[3,2-g][1]benzopyran-6-yl)propanamide
6.4% inhibition at 0.01 mM
-
N-benzyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-butyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-ethyl-3-[4-(furan-2-carbonyl)piperazin-1-yl]-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)propanamide
-
-
N-ethyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-isobutyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-isopentyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-isopropyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-propyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetonitrile
64.3% inhibition at 0.01 mM
-
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid
-
-
2,3,5,6-tetramethyl-7H-furo[3,2-g][1]benzopyran-7-one
-
-
2,3,5-trimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
-
-
2,3,5-trimethyl-6-[3-oxo-3-(piperidin-1-yl)propyl]-7H-furo[3,2-g][1]benzopyran-7-one
-
-
2,3-dimethyl-5-propyl-7H-furo[3,2-g][1]benzopyran-7-one
-
-
3,5-dimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
-
-
3-benzyl-4-methyl-2-oxo-2H-1-benzopyran-7-yl methanesulfonate
-
-
4-(1,3-dihydro-2H-isoindol-2-yl)benzaldehyde
-
-
4-dimethylamino-4-methyl-pent-2-ynthioic acid S-methyl ester
-
-
6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
-
8,9-dimethyl-2,3-dihydrocyclopenta[c]furo[3,2-g][1]benzopyran-4(1H)-one
-
-
9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one
-
-
dichloro-all-trans-retinone
irreversible inhibitor that effectively inhibits isoform RALDH2 in the nanomolar range. I.e. (3E,5E,7E,9E)-1,1-dichloro-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-en-1-yl)deca-3,5,7,9-tetraen-2-one
-
dimethyl ampal thiolester
-
Mg2+
at 30 mM Mg2+, significant inhibition of activity is shown for isoform RALDH2
N,N'-(octane-1,8-diyl)bis(2,2-dichloroacetamide)
-
N,N-diethylaminobenzaldehyde
-
N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
6.25% inhibition at 0.01 mM at pH 7.5, 25°C
-
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid
a 2,4-thiazolidinedione-3-acetic acid derivative
-
[3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
-
6-benzyl-3,5-dimethyl-7H-furo[3,2-g][1]benzopyran-7-one
41.5% inhibition at 0.01 mM
-
6-benzyl-3,5-dimethyl-7H-furo[3,2-g][1]benzopyran-7-one
12.6% inhibition at 0.01 mM
-
Mg2+
at 30 mM Mg2+, significant inhibition of activity is shown for isoform RALDH1
Mg2+
inhibits the aldehyde dehydrogenase activity of ALDH1A1 by inhibiting the dissociation of NADH from the enzyme
N,N'-(octane-1,8-diyl)bis(2,2-dichloroacetamide)
WIN 18,446, strong irreversible inhibition
-
N,N'-(octane-1,8-diyl)bis(2,2-dichloroacetamide)
WIN 18,446, weak inhibition
-
N,N-diethylaminobenzaldehyde
-
-
-
N,N-diethylaminobenzaldehyde
DEAB
-
[3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
a 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivative
-
[3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
a 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivative and a non-competitive inhibitor of ALDH1A3
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity. N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide effectively improves glucose consumption in Hep-G2 cells compared to compound 1 (CM026). Cell viability assays with compounds N-(2-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, and N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide in Hep-G2 cells. Comparison of inhibitory activities on different ALDH isozymes, overview
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity. N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide effectively improves glucose consumption in Hep-G2 cells compared to compound 1 (CM026). Cell viability assays with compounds N-(2-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, and N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide in Hep-G2 cells. Comparison of inhibitory activities on different ALDH isozymes, overview
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity. N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide effectively improves glucose consumption in Hep-G2 cells compared to compound 1 (CM026). Cell viability assays with compounds N-(2-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, and N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide in Hep-G2 cells. Comparison of inhibitory activities on different ALDH isozymes, overview
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoic acid, 3-(7-hydroxy-4-methyl-2-oxo-2H-1-benzopyran-3-yl)propanoic acid, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoic acid, 3-(7-hydroxy-4-methyl-2-oxo-2H-1-benzopyran-3-yl)propanoic acid, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoic acid, 3-(7-hydroxy-4-methyl-2-oxo-2H-1-benzopyran-3-yl)propanoic acid, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
additional information
no inhibition of ALDH1A1 by [3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
-
additional information
no inhibition of ALDH1A1 by [3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
-
additional information
no inhibition of ALDH1A1 by [3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
-
additional information
not inhibited by trans-anethole
-
additional information
not inhibited by trans-anethole
-
additional information
not inhibited by trans-anethole
-
additional information
-
not inhibited by trans-anethole
-
additional information
-
if dithiothreitol is omitted from the elution buffer during RDH13-His6 purification, the purified enzyme has a very low activity, but can be reactivated by the addition of dithiothreitol. Becomes partially inactivated after 20 min of incubation at 37°C. Not inhibited at 0.05 mM by nonanal, 6-cis-nonenal and 2-trans-nonenal, glyceraldehyde and acetoacetyl-coenzyme A, taurocholic acid, 25-hydroxycholesterol and 25-nor-5-cholesten-3-ol-25b-one
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. All tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. All tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. All tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. Almost all tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. Almost all tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. Almost all tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one, and 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one, and 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one, and 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
additional information
not inhibited by trans-anethole
-
additional information
not inhibited by trans-anethole
-
additional information
not inhibited by trans-anethole
-
additional information
-
not inhibited by trans-anethole
-
additional information
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid, a 2,4-thiazolidinedione-3-acetic acid derivative, is inactive as inhibitor
-
additional information
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid, a 2,4-thiazolidinedione-3-acetic acid derivative, is inactive as inhibitor
-
additional information
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid, a 2,4-thiazolidinedione-3-acetic acid derivative, is inactive as inhibitor
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acquired Immunodeficiency Syndrome
Cutting Edge: 4-1BB Controls Regulatory Activity in Dendritic Cells through Promoting Optimal Expression of Retinal Dehydrogenase.
Adenoma
Retinoid acid receptor expression is helpful to distinguish between adenoma and well-differentiated carcinoma in the thyroid.
Alzheimer Disease
Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain.
Asthma
Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma.
Barrett Esophagus
The Microenvironment in Barrett's Esophagus Tissue Is Characterized by High FOXP3 and RALDH2 Levels.
Blindness
Retinal dehydrogenase 12 (RDH12) mutations in leber congenital amaurosis.
Breast Neoplasms
Profiling of the transcriptional response to all-trans retinoic acid in breast cancer cells reveals RARE-independent mechanisms of gene expression.
Carcinoma
Retinoid acid receptor expression is helpful to distinguish between adenoma and well-differentiated carcinoma in the thyroid.
Carcinoma
Vitamin A metabolism is impaired in human ovarian cancer.
Carcinoma, Hepatocellular
Retinal dehydrogenase 5 (RHD5) attenuates metastasis via regulating HIPPO/YAP signaling pathway in Hepatocellular Carcinoma.
Cataract
Molecular Mimicry between Betaine Aldehyde Dehydrogenase of Leptospira and Retinal Dehydrogenase 1 of Human Lens: A Potential Trigger for Cataract Formation in Leptospiral Uveitis Patients.
Cataract
Proteomic analysis of human age-related nuclear cataracts and normal lens nuclei.
Choanal Atresia
A newborn lethal defect due to inactivation of retinaldehyde dehydrogenase type 3 is prevented by maternal retinoic acid treatment.
Colitis
Antibody secreting cells are critically dependent on integrin ?4?7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis.
Crohn Disease
Human CD14+ macrophages in intestinal lamina propria exhibit potent antigen-presenting ability.
Cystic Fibrosis
Retinoic acid signaling regulates murine bronchial tubule formation.
Diabetes Mellitus, Type 2
Raldh3 expression in diabetic islets reciprocally regulates secretion of insulin and glucagon from pancreatic islets.
Endometrial Hyperplasia
From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures.
Esotropia
PLXNC1 and RDH13 associated with bilateral convergent strabismus with exophthalmus in German Brown cattle.
Food Hypersensitivity
Dietary Fiber and Bacterial SCFA Enhance Oral Tolerance and Protect against Food Allergy through Diverse Cellular Pathways.
Glomerulonephritis, IGA
Myofibroblasts acquire retinoic acid-producing ability during fibroblast-to-myofibroblast transition following kidney injury.
Heart Defects, Congenital
ALDH1A2 (RALDH2) genetic variation in human congenital heart disease.
Heart Defects, Congenital
Embryonic retinoic acid synthesis is essential for heart morphogenesis in the mouse.
Hernias, Diaphragmatic, Congenital
Retinal dehydrogenase-2 is inhibited by compounds that induce congenital diaphragmatic hernias in rodents.
Ileitis
Granulocyte-macrophage colony stimulating factor blockade promotes ccr9(+) lymphocyte expansion in Nod2 deficient mice.
Infections
Upregulation of Retinal Dehydrogenase 2 in Alternatively Activated Macrophages during Retinoid-dependent Type-2 Immunity to Helminth Infection in Mice.
Insulin Resistance
Contribution of Hepatic Retinaldehyde Dehydrogenase Induction to Impairment of Glucose Metabolism by High-Fat-Diet Feeding in C57BL/6J Mice.
Insulin Resistance
Retinaldehyde represses adipogenesis and diet-induced obesity.
Leber Congenital Amaurosis
Retinal dehydrogenase 12 (RDH12) mutations in leber congenital amaurosis.
Liver Cirrhosis
Retinol dehydrogenase 13 deficiency diminishes carbon tetrachloride-induced liver fibrosis in mice.
Lymphatic Metastasis
Aldehyde dehydrogenase 3A1 is robustly upregulated in gastric cancer stem-like cells and associated with tumorigenesis.
Metabolic Diseases
Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders.
Moyamoya Disease
Deregulation of Retinaldehyde Dehydrogenase 2 Leads to Defective Angiogenic Function of Endothelial Colony-Forming Cells in Pediatric Moyamoya Disease.
Myopia
Identification of active retinaldehyde dehydrogenase isoforms in the postnatal human eye.
Myopia
Postnatal Chick Choroids Exhibit Increased Retinaldehyde Dehydrogenase Activity During Recovery From Form Deprivation Induced Myopia.
Neoplasm Metastasis
Aldehyde dehydrogenase 3A1 is robustly upregulated in gastric cancer stem-like cells and associated with tumorigenesis.
Neoplasm Metastasis
Retinal dehydrogenase 5 (RHD5) attenuates metastasis via regulating HIPPO/YAP signaling pathway in Hepatocellular Carcinoma.
Neoplasms
Aldehyde dehydrogenase 3A1 is robustly upregulated in gastric cancer stem-like cells and associated with tumorigenesis.
Neoplasms
Development of a Retinal-Based Probe for the Profiling of Retinaldehyde Dehydrogenases in Cancer Cells.
Neoplasms
Diverse actions of retinoid receptors in cancer prevention and treatment.
Neoplasms
Evaluation of spice and herb as phyto-derived selective modulators of human retinaldehyde dehydrogenases using a simple in vitro method.
Neoplasms
From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures.
Neoplasms
Inhibition of ALDH3A1-catalyzed oxidation by chlorpropamide analogues.
Neoplasms
Intestinal bacteria condition dendritic cells to promote IgA production.
Neoplasms
Investigating the Role of Missense SNPs on ALDH 1A1 mediated pharmacokinetic resistance to cyclophosphamide.
Neoplasms
Involvement of aldehyde dehydrogenase 1A2 in the regulation of cancer stem cell properties in neuroblastoma.
Neoplasms
Isolation and Establishment of a Highly Proliferative, Cancer Stem Cell-Like, and Naturally Immortalized Triple-Negative Breast Cancer Cell Line, KAIMRC2.
Neoplasms
Mouse CD11bhigh lung dendritic cells have more potent capability to induce IgA than CD103+ lung dendritic cells in vitro.
Neoplasms
Retinoic acid biosynthesis by normal human breast epithelium is via aldehyde dehydrogenase 6, absent in MCF-7 cells.
Neoplasms
The retinal dehydrogenase/reductase retSDR1/DHRS3 gene is activated by p53 and p63 but not by mutants derived from tumors or EEC/ADULT malformation syndromes.
Nephrosis
Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats.
Neuroblastoma
Involvement of aldehyde dehydrogenase 1A2 in the regulation of cancer stem cell properties in neuroblastoma.
Obesity
Contribution of Hepatic Retinaldehyde Dehydrogenase Induction to Impairment of Glucose Metabolism by High-Fat-Diet Feeding in C57BL/6J Mice.
Obesity
Effects of citral, a naturally occurring antiadipogenic molecule, on an energy-intense diet model of obesity.
Obesity
Retinaldehyde represses adipogenesis and diet-induced obesity.
Pre-Eclampsia
Analysis of the placental tissue transcriptome of normal and preeclampsia complicated pregnancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3.
Prolactinoma
Reduction of retinaldehyde dehydrogenase 1 expression and production in estrogen-induced prolactinoma of rat.
Retinal Degeneration
Levels of retinoic acid and retinaldehyde dehydrogenase expression in eyes of the Mitf-vit mouse model of retinal degeneration.
retinal dehydrogenase deficiency
Rdh13 deficiency weakens carbon tetrachloride-induced liver injury by regulating Spot14 and Cyp2e1 expression levels.
retinal dehydrogenase deficiency
Retinaldehyde dehydrogenase 1 deficiency inhibits PPAR?-mediated bone loss and marrow adiposity.
retinal dehydrogenase deficiency
Retinoic Acid-dependent signaling pathways and lineage events in the developing mouse spinal cord.
retinal dehydrogenase deficiency
Retinol dehydrogenase 13 deficiency diminishes carbon tetrachloride-induced liver fibrosis in mice.
Retinal Dystrophies
RDH12 retinopathy: novel mutations and phenotypic description.
Spinal Cord Injuries
Characterization of retinaldehyde dehydrogenase-2 induction in NG2-positive glia after spinal cord contusion injury.
Spinal Dysraphism
Developing with lethal RA levels: genetic ablation of Rarg can restore the viability of mice lacking Cyp26a1.
Stomach Neoplasms
Aldehyde dehydrogenase 3A1 is robustly upregulated in gastric cancer stem-like cells and associated with tumorigenesis.
Stomach Neoplasms
Filtering High-Dimensional Methylation Marks With Extremely Small Sample Size: An Application to Gastric Cancer Data.
Teratocarcinoma
Molecular identification of a major retinoic-acid-synthesizing enzyme, a retinaldehyde-specific dehydrogenase.
Uveitis
Molecular Mimicry between Betaine Aldehyde Dehydrogenase of Leptospira and Retinal Dehydrogenase 1 of Human Lens: A Potential Trigger for Cataract Formation in Leptospiral Uveitis Patients.
Vision Disorders
Mutations in RDH12 encoding a photoreceptor cell retinol dehydrogenase cause childhood-onset severe retinal dystrophy.
Vitamin A Deficiency
Astrocytes as a regulated source of retinoic acid for the brain.
Vitamin A Deficiency
Cellular expression of retinal dehydrogenase types 1 and 2: effects of vitamin A status on testis mRNA.
Vitamin A Deficiency
Retinal dehydrogenase gene expression in stomach and small intestine of rats during postnatal development and in vitamin A deficiency.
Vitamin A Deficiency
The role of vitamin A in mammalian reproduction and embryonic development.
Vitamin A Deficiency
Vitamin A deficiency induces congenital spinal deformities in rats.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00013
2,3,5-trimethyl-6-[3-oxo-3-(piperidin-1-yl)propyl]-7H-furo[3,2-g][1]benzopyran-7-one
Homo sapiens
pH 7.5, 25°C
-
0.00017
8,9-dimethyl-2,3-dihydrocyclopenta[c]furo[3,2-g][1]benzopyran-4(1H)-one
Homo sapiens
pH 7.5, 25°C
-
0.00121
8-[[4-(3-furoyl)-1-piperazinyl]methyl]-1,3-dimethyl-7-(3-methylbutyl)-3,7-dihydro-1H-purine-2,6-dione
Homo sapiens
pH 7.5, 25°C
-
0.00013
9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one
Homo sapiens
pH 7.5, 25°C
-
0.056
N,N'-(octane-1,8-diyl)bis(2,2-dichloroacetamide)
Homo sapiens
pH 8.0, 25°C, recombinant enzyme
-
0.00018
N,N-diethylaminobenzaldehyde
Homo sapiens
pH 8.0, 25°C, recombinant enzyme
-
0.000059
N-(2-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.000126
N-(2-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.000429
N-(2-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.000872
N-(2-methoxybenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.000149
N-(2-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.000379
N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.000385
N-(3-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.001075
N-(3-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.000966
N-(3-methoxybenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.000715
N-(3-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.001144
N-(4-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.001135
N-benzyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
Homo sapiens
pH 7.5, 25°C
-
0.0054
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid
Homo sapiens
pH 8.0, 25°C, recombinant enzyme
-
0.00027 - 0.00033
2,3,5,6-tetramethyl-7H-furo[3,2-g][1]benzopyran-7-one
-
0.0003 - 0.0004
2,3,5-trimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
-
0.0016 - 0.014
2,3,5-trimethyl-6-[3-oxo-3-(piperidin-1-yl)propyl]-7H-furo[3,2-g][1]benzopyran-7-one
-
0.000069
2,3-dimethyl-5-propyl-7H-furo[3,2-g][1]benzopyran-7-one
Homo sapiens
pH 7.5, 25°C
-
0.00076 - 0.0011
3,5-dimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
-
0.01 - 0.011
3-benzyl-4-methyl-2-oxo-2H-1-benzopyran-7-yl methanesulfonate
-
0.00013 - 0.00017
8,9-dimethyl-2,3-dihydrocyclopenta[c]furo[3,2-g][1]benzopyran-4(1H)-one
-
0.000065
9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one
Homo sapiens
pH 7.5, 25°C
-
0.0045
daidzin
Homo sapiens
pH 7.5, 25°C
0.00019132
dichloro-all-trans-retinone
Homo sapiens
isoform RALDH2, at pH 8.2 and 25°C
-
0.00007 - 0.031
N,N'-(octane-1,8-diyl)bis(2,2-dichloroacetamide)
-
0.0095 - 0.047
N,N-diethylaminobenzaldehyde
-
0.023
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid
Homo sapiens
pH 8.0, 25°C, recombinant enzyme
-
0.0012 - 0.0035
[3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
-
0.00027
2,3,5,6-tetramethyl-7H-furo[3,2-g][1]benzopyran-7-one
Homo sapiens
pH 7.5, 25°C
-
0.00033
2,3,5,6-tetramethyl-7H-furo[3,2-g][1]benzopyran-7-one
Homo sapiens
pH 7.5, 25°C
-
0.0003
2,3,5-trimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
Homo sapiens
pH 7.5, 25°C
-
0.0004
2,3,5-trimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
Homo sapiens
pH 7.5, 25°C
-
0.0016
2,3,5-trimethyl-6-[3-oxo-3-(piperidin-1-yl)propyl]-7H-furo[3,2-g][1]benzopyran-7-one
Homo sapiens
pH 7.5, 25°C
-
0.014
2,3,5-trimethyl-6-[3-oxo-3-(piperidin-1-yl)propyl]-7H-furo[3,2-g][1]benzopyran-7-one
Homo sapiens
pH 7.5, 25°C
-
0.00076
3,5-dimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
Homo sapiens
pH 7.5, 25°C
-
0.0011
3,5-dimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
Homo sapiens
pH 7.5, 25°C
-
0.01
3-benzyl-4-methyl-2-oxo-2H-1-benzopyran-7-yl methanesulfonate
Homo sapiens
pH 7.5, 25°C
-
0.011
3-benzyl-4-methyl-2-oxo-2H-1-benzopyran-7-yl methanesulfonate
Homo sapiens
pH 7.5, 25°C
-
0.00013
8,9-dimethyl-2,3-dihydrocyclopenta[c]furo[3,2-g][1]benzopyran-4(1H)-one
Homo sapiens
pH 7.5, 25°C
-
0.00017
8,9-dimethyl-2,3-dihydrocyclopenta[c]furo[3,2-g][1]benzopyran-4(1H)-one
Homo sapiens
pH 7.5, 25°C
-
0.00007
N,N'-(octane-1,8-diyl)bis(2,2-dichloroacetamide)
Homo sapiens
pH 8.0, 25°C, recombinant enzyme
-
0.031
N,N'-(octane-1,8-diyl)bis(2,2-dichloroacetamide)
Homo sapiens
pH 8.0, 25°C, recombinant enzyme
-
0.0095
N,N-diethylaminobenzaldehyde
Homo sapiens
pH 8.0, 25°C, recombinant enzyme
-
0.047
N,N-diethylaminobenzaldehyde
Homo sapiens
pH 8.0, 25°C, recombinant enzyme
-
0.0012
[3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
Homo sapiens
pH 8.0, 25°C, recombinant enzyme
-
0.0035
[3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
Homo sapiens
pH 8.0, 25°C, recombinant enzyme
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Sladek, N.E.
Human aldehyde dehydrogenases: Potential pathological, pharmacological, and toxicological impact
J. Biochem. Mol. Toxicol.
17
7-23
2003
Homo sapiens
brenda
Moreb, J.S.; Gabr, A.; Vartikar, G.R.; Gowda, S.; Zucali, J.R.; Mohuczy, D.
Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde
J. Pharmacol. Exp. Ther.
312
339-345
2005
Homo sapiens
brenda
Belyaeva, O.V.; Korkina, O.V.; Stetsenko, A.V.; Kedishvili, N.Y.
Human retinol dehydrogenase 13 (RDH13) is a mitochondrial short-chain dehydrogenase/reductase with a retinaldehyde reductase activity
FEBS J.
275
138-147
2008
Homo sapiens
brenda
Marchitti, S.A.; Deitrich, R.A.; Vasiliou, V.
Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase
Pharmacol. Rev.
59
125-150
2007
Homo sapiens (O94788)
brenda
Collard, F.; Vertommen, D.; Fortpied, J.; Duester, G.; Van Schaftingen, E.
Identification of 3-deoxyglucosone dehydrogenase as aldehyde dehydrogenase 1A1 (retinaldehyde dehydrogenase 1)
Biochimie
89
369-373
2007
Homo sapiens, Mus musculus
brenda
Kurth, I.; Thompson, D.A.; Ruether, K.; Feathers, K.L.; Chrispell, J.D.; Schroth, J.; McHenry, C.L.; Schweizer, M.; Skosyrski, S.; Gal, A.; Huebner, C.A.
Targeted disruption of the murine retinal dehydrogenase gene Rdh12 does not limit visual cycle function
Mol. Cell. Biol.
27
1370-1379
2007
Homo sapiens, Mus musculus
brenda
Kirschner, R.D.; Rother, K.; Mueller, G.A.; Engeland, K.
The retinal dehydrogenase/reductase retSDR1/DHRS3 gene is activated by p53 and p63 but not by mutants derived from tumors or EEC/ADULT malformation syndromes
Cell Cycle
9
2177-2188
2010
Homo sapiens
brenda
Bchini, R.; Vasiliou, V.; Branlant, G.; Talfournier, F.; Rahuel-Clermont, S.
Retinoic acid biosynthesis catalyzed by retinal dehydrogenases relies on a rate-limiting conformational transition associated with substrate recognition
Chem. Biol. Interact.
202
78-84
2013
Homo sapiens, Rattus norvegicus
brenda
Bchini, R.; Vasiliou, V.; Branlant, G.; Talfournier, F.; Rahuel-Clermont, S.
Retinoic acid biosynthesis catalyzed by retinal dehydrogenases relies on a rate-limiting conformational transition associated with substrate recognition
Chem. Biol. Interact.
202
78-84
2013
Homo sapiens (P00352), Homo sapiens, Rattus norvegicus (Q63639)
brenda
Ma, Z.; Jiang, L.; Li, G.; Liang, D.; Li, L.; Liu, L.; Jiang, C.
Design, synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity
Bioorg. Chem.
101
103971
2020
Homo sapiens (O94788), Homo sapiens (P00352), Homo sapiens (P47895)
brenda
Harper, A.R.; Le, A.T.; Mather, T.; Burgett, A.; Berry, W.; Summers, J.A.
Design, synthesis, and ex vivo evaluation of a selective inhibitor for retinaldehyde dehydrogenase enzymes
Bioorg. Med. Chem.
26
5766-5779
2018
Gallus gallus, Gallus gallus (O93344), Gallus gallus (P27463), Homo sapiens (O94788)
brenda
Bui, T.B.C.; Nosaki, S.; Kokawa, M.; Xu, Y.; Kitamura, Y.; Tanokura, M.; Hachimura, S.; Miyakawa, T.
Evaluation of spice and herb as phyto-derived selective modulators of human retinaldehyde dehydrogenases using a simple in vitro method
Biosci. Rep.
41
BSR20210491
2021
Homo sapiens (O94788), Homo sapiens (P00352), Homo sapiens (P47895), Homo sapiens
brenda
Jimenez, R.; Pequerul, R.; Amor, A.; Lorenzo, J.; Metwally, K.; Aviles, F.X.; Pares, X.; Farres, J.
Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents kinetic characterization and effect on human cancer cells
Chem. Biol. Interact.
306
123-130
2019
Homo sapiens (O94788), Homo sapiens (P00352), Homo sapiens (P47895)
brenda
Hu, H.; Xu, L.; Luo, S.J.; Xiang, T.; Chen, Y.; Cao, Z.R.; Zhang, Y.J.; Mo, Z.; Wang, Y.; Meng, D.F.; Yu, L.; Lin, L.Z.; Zhang, S.J.
Retinal dehydrogenase 5 (RHD5) attenuates metastasis via regulating HIPPO/YAP signaling pathway in hepatocellular carcinoma
Int. J. Med. Sci.
17
1897-1908
2020
Homo sapiens
brenda
Buchman, C.D.; Hurley, T.D.
Inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives
J. Med. Chem.
60
2439-2455
2017
Homo sapiens (O94788), Homo sapiens (P00352), Homo sapiens (P47895)
brenda
Wang, B.; Chen, X.; Wang, Z.; Xiong, W.; Xu, T.; Zhao, X.; Cao, Y.; Guo, Y.; Li, L.; Chen, S.; Huang, S.; Wang, X.; Fang, M.; Shen, Z.
Aldehyde dehydrogenase 1A1 increases NADH levels and promotes tumor growth via glutathione/dihydrolipoic acid-dependent NAD+ reduction
Oncotarget
8
67043-67055
2017
Homo sapiens (P00352)
brenda
Park, J.W.; Jung, K.H.; Lee, J.H.; Moon, S.H.; Cho, Y.S.; Lee, K.H.
Inhibition of aldehyde dehydrogenase 1 enhances the cytotoxic effect of retinaldehyde on A549 cancer cells
Oncotarget
8
99382-99393
2017
Homo sapiens
brenda
Dominguez, M.; Pequerul, R.; Alvarez, R.; Gimenez-Dejoz, J.; Birta, E.; Porte, S.; Ruehl, R.; Pares, X.; Farres, J.; de Lera, A.
Synthesis of apocarotenoids by acyclic cross metathesis and characterization as substrates for human retinaldehyde dehydrogenases
Tetrahedron
74
2567-2574
2018
Homo sapiens (O94788), Homo sapiens (P00352), Homo sapiens (P47895)
-
brenda